News

1 to 9 of 17 results

New drugs and biosimilars to drive rheumatoid arthritis to $19.3 billion by 2023

New drugs and biosimilars to drive rheumatoid arthritis to $19.3 billion by 2023

13-01-2015

The launch of novel drugs and biosimilars will drive steady growth in the global rheumatoid arthritis…

AmgenAnti-Arthritics/RheumaticsEnbrelHumiraMarkets & MarketingPharmaceuticalResearchUSA

EMA responds to Ombudsman questioning of AbbVie trial redactions

13-11-2014

The European Medicines Agency says it has taken note of the European Ombudsman’s recent remarks on…

AbbVieAnti-Arthritics/RheumaticsEuropeHumiraPharmaceuticalRegulationResearch

New Ph III data to support filing for AbbVie’s Humira in HS

13-10-2014

US pharma company AbbVie has reported new data with its mega blockbuster arthritis drug Humira (adalimumab)…

AbbVieAnti-Arthritics/RheumaticsDermatologicalsHumiraPharmaceuticalResearch

Ph III study of Amgen’s Humira biosimilar ABP 501 meets endpoint in psoriasis

Ph III study of Amgen’s Humira biosimilar ABP 501 meets endpoint in psoriasis

09-10-2014

US biotech major Amgen says its Phase III study evaluating the efficacy and safety of its biosimilar…

AbbVieABP 501AmgenAnti-Arthritics/RheumaticsBiosimilarsBiotechnologyDermatologicalsHumiraResearchUSA

Opportunity for emerging agents in Crohn’s disease, report finds

Opportunity for emerging agents in Crohn’s disease, report finds

18-09-2014

New research from Decision Resources Group has found that only a small proportion of patients with Crohn's…

Anti-Arthritics/RheumaticsBiosimilarsEntyvioHumiraPharmaceuticalRemicadeResearchStelaraUSAXeljanz

Positive new data for AbbVie’s Humira in HS

Positive new data for AbbVie’s Humira in HS

11-09-2014

US pharma group AbbVie has released results from a Phase III pivotal study demonstrating that its blockbuster…

AbbVieAnti-Arthritics/RheumaticsDermatologicalsHumiraPharmaceuticalResearch

EULAR highlights: Celgene's apremilast; AbbVie's Humira; and Lilly's baricitinib

13-06-2013

Among highlights of the ongoing European League Against Rheumatism (EULAR) in Madrid, Spain, US biotech…

AbbVieAnti-Arthritics/RheumaticsapremilastbaricitinibBiotechnologyCelgeneEli LillyHumiramethotrexatePharmaceuticalResearch

Bristol-Myers Orencia equals Humira in head-to-head AMPLE RA study

12-06-2013

US drug major Bristol-Myers Squibb (NYSE: BMY) has announced the results of year two data from AMPLE…

AbbVieAnti-Arthritics/RheumaticsBristol-Myers SquibbHumiraOrenciaPharmaceuticalResearch

1 to 9 of 17 results

COMPANY SPOTLIGHT

Menarini

Back to top